|
|
|
|
Office Locations:
|
200 Clarendon St.
Boston, MA 02116
Phone: 617-516-2000
Fax: 617-516-2010
| |
|
|
|
|
- Early
- Expansion
- Growth
- Middle Market
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. Bain Capital Life Sciences targets four types of investment opportunities: Engagement with companies at the critical development stages of innovation; Partnering with companies to accelerate and expand platforms; Engaging with companies at a crossroads to create value; and Collaborating with the Bain Capital platform to invest in and support larger companies. Bain Capital Life Sciences has made 51 investments globally.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Adam M. Koppel | |
MD, PhD | |
Managing Director | |
| Andrew Hack | |
MD, PhD | |
Managing Director | |
| Jeffrey Schwartz | |
| |
Managing Director | |
| Kristen Deftos | |
| |
Sr VP | |
|
|
|
|
|
|
|
|
|
